Current Status of BTKi Treatment for CLL/SLL in China

Launched by THE FIRST AFFILIATED HOSPITAL WITH NANJING MEDICAL UNIVERSITY · Jul 14, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how well a type of treatment called BTK inhibitors is working for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in China. BTK inhibitors have become a common choice for treating these conditions, but there hasn't been enough large-scale research to understand how they are being used in everyday practice. The goal of this study is to gather information from multiple hospitals about the use of BTK inhibitors, the factors that affect treatment choices, and to find better ways to treat patients.

To join this study, participants must be at least 18 years old and have a confirmed diagnosis of CLL or SLL. They should also have received treatment with a BTK inhibitor between February 2023 and February 2024. Patients with other types of lymphoma or those who the doctors feel shouldn't be part of the study will not be included. If you decide to participate, you can expect to share your treatment experiences, which will help researchers understand how to improve care for others facing similar health challenges.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years;
• • Patients with a confirmed diagnosis of CLL/SLL;
• • Received BTK inhibitor treatment between February 2023 and February 2024.
• Exclusion Criteria:
• • Patients with other types of lymphoma;
• • Cases deemed unsuitable for inclusion in this study by the investigators.